SynthesisCancer immunology, immunotherapy : CII2022

Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.

Gilbert Lazarus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.